Guggenheim Capital’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-56,729
| Closed | -$2.23M | – | 1961 |
|
|
2023
Q2 | $2.23M | Buy |
56,729
+269
| +0.5% | +$9.49K | 0.02% | 811 |
|
|
2023
Q1 | $1.37M | Buy |
+56,460
| New | +$1.24M | 0.01% | 1021 |
|
|
2017
Q3 | – | Sell |
-10,030
| Closed | -$26K | – | 2864 |
|
|
2017
Q2 | $26K | Sell |
10,030
-1,015
| -9% | -$2.77K | ﹤0.01% | 2771 |
|
|
2017
Q1 | $40K | Sell |
11,045
-407,675
| -97% | -$1.72M | ﹤0.01% | 2746 |
|
|
2016
Q4 | $2.02M | Buy |
418,720
+363,503
| +658% | +$10.8M | 0.01% | 1682 |
|
|
2016
Q3 | $2.55M | Sell |
55,217
-5
| -0% | -$282 | 0.01% | 1460 |
|
|
2016
Q2 | $2.82M | Sell |
55,222
-7,353
| -12% | -$365K | 0.01% | 1337 |
|
|
2016
Q1 | $2.65M | Sell |
62,575
-8,179
| -12% | -$417K | 0.01% | 1382 |
|
|
2015
Q4 | $5.56M | Buy |
70,754
+29,557
| +72% | +$1.71M | 0.02% | 969 |
|
|
2015
Q3 | $1.67M | Buy |
+41,197
| New | +$2.18M | 0.01% | 1730 |
|
|
2014
Q4 | – | Sell |
-83,715
| Closed | -$3.26M | – | 3131 |
|
|
2014
Q3 | $3.26M | Buy |
83,715
+54,687
| +188% | +$2.15M | 0.01% | 1428 |
|
|
2014
Q2 | $1.23M | Buy |
+29,028
| New | +$1.07M | ﹤0.01% | 2147 |
|
Guggenheim Capital's ISEE Position: Q3 2023 in Review
Guggenheim Capital sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 56,729 shares — an estimated $2.23M sold.
Guggenheim Capital first reported a position in ISEE in Q2 2014 and held it in 12 quarters. The position peaked at $5.56M in Q4 2015. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Guggenheim Capital reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Guggenheim Capital sold 56,729 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $2.23M.
- Guggenheim Capital first reported a position in IVERIC bio, Inc. Common Stock in Q2 2014 and held it in 12 quarters.
- Guggenheim Capital's IVERIC bio, Inc. Common Stock position peaked at $5.56M in Q4 2015.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Guggenheim Capital's 13F filing for Q3 2023, filed 14 Nov 2023.